Dendreon may be on its last legs , but former CEO Mitchell Gold is happily entrenched in other projects: He’s launching a next-generation immunotherapy startup called Alpine Immune Sciences , seeding about $1.3 million into the company through his investment firm, Alpine BioVentures .
